Literature DB >> 25339996

Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy.

Eleonora Dondossola1, Angelo Corti2, Richard L Sidman3, Wadih Arap4, Renata Pasqualini4.   

Abstract

Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b+CD13+ myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b+CD13+ myeloid cells could become a non-malignant target for the development of novel anticancer regimens.

Entities:  

Keywords:  CD13; angiogenesis; bone marrow-derived cells; mouse models; tumor

Year:  2014        PMID： 25339996      PMCID： PMC4203577          DOI： 10.4161/onci.27716

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment.

Authors:  Liliana Guzman-Rojas; Roberto Rangel; Ahmad Salameh; Julianna K Edwards; Eleonora Dondossola; Yun-Gon Kim; Alan Saghatelian; Ricardo J Giordano; Mikhail G Kolonin; Fernanda I Staquicini; Erkki Koivunen; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  Targeted drug delivery and penetration into solid tumors.

Authors:  Angelo Corti; Fabio Pastorino; Flavio Curnis; Wadih Arap; Mirco Ponzoni; Renata Pasqualini
Journal:  Med Res Rev       Date:  2011-02-01       Impact factor: 12.944

Review 3.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

4.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

Authors:  R Pasqualini; E Koivunen; R Kain; J Lahdenranta; M Sakamoto; A Stryhn; R A Ashmun; L H Shapiro; W Arap; E Ruoslahti
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

5.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

Authors:  W Arap; R Pasqualini; E Ruoslahti
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

Review 6.  Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors.

Authors:  Seth B Coffelt; Claire E Lewis; Luigi Naldini; J Martin Brown; Napoleone Ferrara; Michele De Palma
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

7.  CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis.

Authors:  Eleonora Dondossola; Roberto Rangel; Liliana Guzman-Rojas; Elena M Barbu; Hitomi Hosoya; Lisa S St John; Jeffrey J Molldrem; Angelo Corti; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

8.  Impaired angiogenesis in aminopeptidase N-null mice.

Authors:  Roberto Rangel; Yan Sun; Liliana Guzman-Rojas; Michael G Ozawa; Jessica Sun; Ricardo J Giordano; Carolyn S Van Pelt; Peggy T Tinkey; Richard R Behringer; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

Review 9.  Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis.

Authors:  Michele De Palma; Luigi Naldini
Journal:  Biochim Biophys Acta       Date:  2006-06-27

Review 10.  The moonlighting enzyme CD13: old and new functions to target.

Authors:  Paola Mina-Osorio
Journal:  Trends Mol Med       Date:  2008-07-05       Impact factor: 11.951
  10 in total
  3 in total

1.  Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction.

Authors:  Carol W Chen; Leo L Wang; Samir Zaman; Jon Gordon; Maria F Arisi; Chantel M Venkataraman; Jennifer J Chung; George Hung; Ann C Gaffey; Lynn A Spruce; Hossein Fazelinia; Robert C Gorman; Steven H Seeholzer; Jason A Burdick; Pavan Atluri
Journal:  Cardiovasc Res       Date:  2018-06-01       Impact factor: 10.787

Review 2.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

3.  CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.

Authors:  Juan Manuel Domínguez; Gema Pérez-Chacón; María José Guillén; María José Muñoz-Alonso; Beatriz Somovilla-Crespo; Danay Cibrián; Bárbara Acosta-Iborra; Magdalena Adrados; Cecilia Muñoz-Calleja; Carmen Cuevas; Francisco Sánchez-Madrid; Pablo Avilés; Juan M Zapata
Journal:  J Hematol Oncol       Date:  2020-04-07       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.